Enzychem Lifesciences
Seoul, South KoreaFounded 1999Industry
Enzychem is a Korean drug developer whose EC-18 is an investigational countermeasure for acute radiation syndrome. It has FDA orphan drug designation and a material transfer agreement with the Armed Forces Radiobiology Research Institute.
What it does
Threats covered
Categories
Profile
Enzychem Lifesciences is a Seoul-based drug developer listed on KOSDAQ under 183490, and the part of its work relevant here is EC-18, which it is developing for acute radiation syndrome. The company was founded in 1999.
More profile
In 2025 it began a 12-month study of gastrointestinal acute radiation syndrome with the Korea Institute of Radiological and Medical Sciences, and in February 2026 it reported successful preliminary rodent experiments in which EC-18 showed potential radioprotective and radiation-mitigating effects. In 2026 it announced follow-up research on gastrointestinal acute radiation syndrome and widened the collaboration with the institute to cover radiation-induced dermatitis, according to a business-press report dated 4 August 2026.
The results are preclinical and the company's other programmes address non-radiological indications. No funding amounts or government radiological-countermeasure contracts were found in the sources read.
Ownership
Publicly listed on KOSDAQ (183490)
Parent: none (publicly listed) (checked)
Sources (4)
Not verified or not found
- Funding amounts and government contracts for the radiation programme: none found.
- Clinical status of EC-18 for acute radiation syndrome: preclinical results only were read.
- Two Korean-language company pages were read via search summaries only.
Questions
What does Enzychem Lifesciences do?
Enzychem is a Korean drug developer whose EC-18 is an investigational countermeasure for acute radiation syndrome. It has FDA orphan drug designation and a material transfer agreement with the Armed Forces Radiobiology Research Institute.
Where is Enzychem Lifesciences based?
HQ (as found): Seoul. HQ country: KR.
Who owns Enzychem Lifesciences?
Publicly listed on KOSDAQ (183490). Parent: none (publicly listed) (checked)
Profiles are compiled from public sources and sampled-checked, not fully audited. Last verified 17 October 2026. Report a correction